ArticleThe Journal of experimental medicine2015

CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo.

Nicole Mende et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.